Geron Corporation Scheduled to Report Third Quarter Earnings on November 4
Geron Corporation (GERN) is set to release its third-quarter financial results before the market opens on Wednesday, November 4. Market analysts are looking for a consensus earnings per share (EPS) of -$0.01 and revenue expectations of approximately $60.36 million, which would represent a significant year-over-year increase of 27.9%. The upcoming report follows a period of volatility for the company, including recent stock price fluctuations linked to the discontinuation of a late-stage trial for Rytelo and previous revenue beats driven by the same product. Investors will be closely monitoring how current sales trends and management's strategic response to increasing competition in the myelofibrosis sector influence the company's financial trajectory.
Tickers: $GERN
Topics: biotechnology earnings announcement EPS estimates revenue estimates
Read the full article at Seeking Alpha
Part of the story Manulife Reports Record Core Earnings and Strong Asian Growth in Q3 2026 (106 articles)